Beta Bionics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
2.4%projected annual EPS growth
Analyst Coverage
10analysts covering
FY Revenue (est.)
$133.3Mnext fiscal year
FY EPS (est.)
-$2.11next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results Release | 15 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Annually100.3MTarget: $131 million to $136 million
Pharmacy Benefit (PBP) Channel Revenue Mix Annually0.2Target: 37% to 39%
Gross Margin Annually55.4%Target: 57.5% to 59.5%
Installed iLet User Base Quarterly35K
Watch Items
- FDA Warning Letter RemediationTrigger: FDA close-out letter or follow-up inspection clearanceAction: Monitor quality system updates, Form 483 response timelines, and associated remediation expenses in Irvine, CA facility.
- Mint Patch Pump Commercialization TimelineTrigger: FDA 510(k) submission or clearanceAction: Track updates to the commercialization timeline for the Mint patch pump prototype to compete with Insulet's Omnipod.
- Bihormonal iLet System Clinical ProgressTrigger: Initiation of Phase 2b pivotal-enabling trialAction: Monitor progress of the bihormonal system (insulin + glucagon) following the completion of the Phase 2a feasibility trial in New Zealand.
Research as of 20 Jun 2026